BioConstBioConst 生物常量

研究・一般情報としての参考です。BioConst は内容を継続的に修正しますが、誤りを含む可能性があります。診断、投薬、検査、治療の判断は医師の指導に従ってください。

脂肪肝と肝内脂肪沈着

肝内脂肪は代謝文脈を反映し、線維化リスクと合わせて読む必要がある。

医師と一緒に読むページ

このトピックは、検査や画像の解釈、神経・心臓・血液・肝臓・腎臓・肺の疾患、手術、薬剤、複雑な基礎疾患を含むことがあります。BioConst は説明に限定し、個人判断や対応の助言は行いません。

これは何か

Fatty liver disease means fat is present in the liver and is interpreted with metabolic and fibrosis context.[1,2]

感じられること

  • NAFLD is also referred to as MASLD in NIDDK patient material.[1,2]
  • Blood tests, imaging, and sometimes biopsy may enter diagnosis and staging context.[1,2]

主要変数

Hepatic steatosis

Fat in the liver is the structural starting point.[1,2]

Alanine aminotransferase (ALT)

ALT may be elevated, but enzymes alone do not determine severity.[1,2]

Liver fibrosis

Fibrosis context changes the meaning of fatty liver.[1,2]

なぜ起こるか

  • Metabolic factors such as obesity, insulin resistance, diabetes, triglycerides, and metabolic syndrome can increase risk.[1,2]
  • Other causes of liver fat and alcohol-associated liver disease need clinical separation.[1,2]

臨床対応の方向

  • Clinical teams may use history, exam, labs, imaging, and specialist review depending on fatty liver context.[1,2]
  • BioConst explains the map and does not diagnose, rank urgency, choose tests, or recommend treatment.[1,2]

よくある誤解

  • Fat on imaging does not automatically identify inflammation.[1,2]
  • Normal enzymes do not automatically exclude clinically important disease.[1,2]
  • Fatty liver is not a supplement target or a one-number problem.[1,2]

関連 wiki 変数